Invesco Exchange-Traded Fund Trust II has released its latest financial update, showcasing its assets and liabilities as part of its ongoing commitment to transparency. The report, filed on October 30, 2026, reveals total assets of approximately $2.29 million and liabilities of about $499.53.
This update is significant for Invesco as it reflects the company's financial health and operational stability in the competitive investment sector. As an investment company, Invesco operates within a landscape that is constantly evolving, and such disclosures are crucial for maintaining investor confidence.
Background
Invesco Exchange-Traded Fund Trust II, identified by the CIK 0001378872, is categorized under the investment entity type. The company is known for its range of investment products, particularly in the exchange-traded fund (ETF) space. Recent filings include multiple NPORT-P submissions on October 30, 2026, indicating a proactive approach to regulatory compliance and investor communication.
What the Filing Says
The latest filing, accession number 0001378872-26-001868, details the financial status of Invesco's QQQ Low Volatility ETF. The report states that the total assets amount to $2,288,247.35, while total liabilities stand at $499.53, leading to net assets of $2,287,747.82. The filing emphasizes the importance of these figures in assessing the fund's performance and stability.
Impact
This financial update may affect various stakeholders, including current and potential investors, who rely on accurate and timely information to make informed decisions. Additionally, competitors in the ETF market will likely analyze these figures to gauge Invesco's market position and strategies.
What's Next
The filing does not specify what happens next for Invesco Exchange-Traded Fund Trust II. However, continuous monitoring of their financial health and further disclosures are expected as part of their regulatory obligations.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






